420 with CNW — Another Push Is Underway in Florida to Legalize Recreational Cannabis

Floridians could be able to purchase and use recreational cannabis legally in the next few years if a proposed constitutional amendment that was filed last week is successful. Backed by country-music duo the Bellamy Brothers and Trulieve, currently the largest medical-cannabis operator in Florida, the measure would legalize the use of recreational marijuana by people aged 21 and older.

The Tallahassee-based medical marijuana operator contributed $5 million to help get the constitutional amendment to the 2024 ballot. The measure is also expected to receive support from other multistate medical cannabis companies. The proposed amendment was filed on Monday at the Florida Division of Elections and would allow the possession, purchase, and use of cannabis and cannabis products for nonmedical use.

Voters in Florida legalized medical marijuana via a constitutional amendment in 2016 after a failed attempt in 2014. The 2014 constitutional amendment failed to advance because it required at least 60% rather than a simple majority to receive approval. Soon after the 2016 amendment passed, Florida lawmakers launched a vertically integrated system that allowed companies to handle one or more stages of production.

However, this vertically integrated system has been criticized for significantly increasing operational costs and locking out small entrepreneurs who don’t have access to large capital. If the new constitutional amendment, dubbed the “Adult Person Use of Marijuana” is passed by voters, lawmakers will have to figure out how to structure the industry. Activists behind the measure will have to collect around 900,000 petition signatures to qualify for the 2024 ballot.

Backers believe the measure will meet the Florida Supreme Court requirements even though past adult-use cannabis initiatives have failed to advance. Kim Rivers, the CEO of Trulieve, says the proposed amendment is all about increasing access to cannabis in the state. She says that Trulieve, which currently runs around 119 medical cannabis dispensaries, is looking to increase access to safe, high-quality cannabis products that can give people more control over their medical journeys.

News Service reports that the amendment would allow the cultivation, processing, manufacturing, selling and distribution of cannabis products at medical cannabis treatment centers. According to musical duo the Bellamy Brothers, Florida is now ready for recreational marijuana. In an email to News Service of Florida, members of the group said that they have seen the benefits of marijuana as they traveled the country. The Florida natives have a ranch in Pasco County, and they have already partnered with Trulieve to produce a line of marijuana products.

As more states seek to legalize recreational marijuana, companies such as Flora Growth Corp. (NASDAQ: FLGC) will have a larger pool of potential markets to choose from when expanding their footprint across the country and beyond.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Cilicon, Vape-Jet Collaborate to Deliver Intelligent, Integrated Vaporizer Solution

Cilicon, a global provider of cannabis vape hardware, together with Vape-Jet, a U.S.-based infrastructure platform for cannabis oil-filling, today announced the forming of an official partnership to provide an intelligent, one-stop product solution for global cannabis brands. With a mutual understanding of the value of technology for business growth in today’s digital economy, Cilicon and Vape-Jet have launched services for cannabis vaping tech development, hardware manufacturing and filling machines for all brands in the cannabis vaporization industry. The partnership aims to reduce the time and financial budget for industry practitioners focused on cannabis vaporization with smart technology and integrated services.

“We aim to provide more integrated, hassle-free, smarter hardware, from filling to vaping, through our collaboration with Vape-Jet,” said Cilicon Chief Brand Officer Chris Lin. “This daily-changing industry requires us to work closer than ever to bring ‘real’ stuff to our cannabis vapor communities and cannabis companies. Working with Vape-Jet absolutely fits our values and culture, and we bond together to provide benefits to change the industry’s pain points and unsolved problems. To make the whole journey from filling to final vaping easier and smarter.”

To view the full press release, visit https://cnw.fm/9rLYI

About Cilicon

Cilicon was born with one dream: to improve everyday lives through vaporization technology with innovation, enthusiasm and compassion. Innovation in its blood, Cilicon is tired of inferior products driving out high-quality products and messing with the market. Therefore, Cilicon was founded without compromising quality, safety and customer satisfaction. Cilicon derives a game-changing platform from generating diverse cannabis vaporizer options available for increasing customer brand competitiveness from the crowd. For Cilicon, brand success is its priority and customer satisfaction matters!

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Florida Agriculture Commissioner Calls DOJ Memo on Gun Rights Lawsuit Insulting

The agriculture commissioner in Florida has described as “insulting” the memo the U.S. Department of Justice filed supporting its motion to dismiss a lawsuit challenging the denial of the right to buy a firearm by users of medical marijuana. The said lawsuit was filed by Commissioner Nikki Fried in April 2022.

No one is surprised that the DOJ asked the court to dismiss this lawsuit, but the contents of the memo the federal agency penned has attracted widespread criticism from several quarters. For starters, advocates have taken exception to the description of medical marijuana users, such as terminally ill cancer patients and military veterans suffering from chronic pain, as people who are too dangerous to be trusted with firearms.

Fried and other reform activists say describing people in dire need of medical marijuana in such an insensitive way is insulting and disappointing given the sizeable body of scientific evidence backing the therapeutic benefits of marijuana. They also say that the DOJ is insisting on taking a position that is a relic of the reefer madness period while the world, and specifically the American public, has moved past such stereotypes.

More criticism was also triggered by the DOJ using centuries’ old case law to back up its position on gun rights for users of medical marijuana. The department specifically wrote that its stance is supported by bans on gun ownership by Native Americans, panhandlers, Catholics and habitual drug users, and this supposedly justifies its insistence that medical marijuana users shouldn’t be allowed to acquire firearms. The DOJ doesn’t at any point recognize that the case law it is citing was discriminatory and that the country has since made adjustments in its actions.

The case law citations included in the DOJ memo were a direct reply to the petitioners’ inclusion of a ruling made by the Supreme Court in New York stipulating that the amendment to bear firearms is supreme and that any attempt to restrict such rights can only happen if such an infringement is in line with the historical circumstances and intent of the amendment.

The attorneys representing Fried and the other plaintiffs are now working to respond to the last-minute memo filed by the DOJ. It should be noted that Fried is contesting to stand against Governor Ron DeSantis during the November polls. She says that if she is elected to that office, she will have no problem involving her new office in this case since it is a matter to which she is committed.

The sentiments implicit in the DOJ response are likely to rub industry actors such as Advanced Container Technologies Inc. (OTC: ACTX) the wrong way since they are working toward changing the attitude and sentiment toward marijuana users generally and particularly medical marijuana users.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Finds Marijuana Legalization Reduces Incidents of Synthetic Cannabinoid Poisoning

Although synthetic cannabinoids such as Spice and K2 are much more potent than natural cannabinoids, they are often mixed with dangerous chemicals, including stimulants, blood thinners and opioids that can make them deadly. An outbreak of synthetic cannabinoids contaminated with anticoagulants in 2018 caused excessive bleeding that affected more than 300 people and took at least eight lives.

A study using data sourced from the National Poison Data System (NPDS) recently revealed that states with legal marijuana access record significantly fewer synthetic cannabinoid poisoning cases. Study authors hypothesize that cannabis policies that allow legal sales provide little incentive for people to use synthetic cannabinoids, which are harder to spot in drug tests but can result in deadly health outcomes for users.

Published in the “Journal of Clinical Toxicology,” the study reported that states with “permissive” marijuana policies had 37% fewer cases of synthetic cannabinoid poisoning annually from 2016 to 2019. States with medical cannabis programs, which generally allow patients to use high-THC marijuana products for medical purposes, had 14% fewer cases of synthetic cannabinoid poisoning.

Furthermore, states that only allowed medical cannabis use had 36% fewer cases of reported poisonings compared to states with recreational markets that allowed cannabis sales to all adults aged 21 and over. The study recorded a total of 7,600 reported cases of synthetic cannabinoid poisoning from 2016 to 2019, with 64.8% of the cases needing medical attention. The study also reported that 61 people lost their lives due to synthetic cannabinoid exposure during the study period.

The research involved researchers from the University of Arkansas College of Medicine, Oregon Health Authority and the Washington State University College of Nursing. The groups divided states into three categories: medical (states that allow high-THC products), permissive (states where recreational cannabis is legal) and restrictive (states that don’t allow both medical and recreational cannabis).

According to lead study author and WSU associate professor of nursing Tracy Klein, their study provides evidence of the potential public health benefits of legalizing marijuana and creating regulated cannabis markets. Synthetic cannabinoids are especially attractive to people who could lose their employment due to cannabis use because the substances don’t usually show up in drug tests for delta-9 THC, the main psychoactive agent in cannabis. This includes people in law enforcement, the military and other occupations that require regular drug tests. Klein says that based on this study and prior research, cannabis users are much more unlikely to choose synthetic cannabinoids when they can purchase legal cannabis without any legal ramifications.

These findings are a boost to the people who have always believed that allowing cannabis companies such as American Cannabis Partners to operate legally is a sensible move in several ways, including protecting public health.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – AmeriCann Inc. (ACAN) Reports Record Net Income, Revenue

AmeriCann (OTCQB: ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, has released its financial and operational results for its fiscal quarter ending June 30, 2022. According to the company, July revenue set an all-time monthly record. Numbers showed a significant increase in year-over-year quarterly net income and revenue, with both being records for the Company for the quarter ending June 2022. Revenue increased over 36% for the quarter ended June 2022 relative to the same quarter 2021, an increase of $213,188. Quarterly gross margins were 98.5%. The company attributed the increased revenue to products produced and manufactured at Building 1, AmeriCann’s initial building at its Massachusetts Cannabis Center development in Freetown, Massachusetts. The 30,000-square-foot cultivation greenhouse and processing facility features utilizes AmeriCann’s proprietary Cannopy cultivation system and is occupied by Bask Inc., an existing licensed vertically integrated cannabis operator in Massachusetts. AmeriCann receives base rent and a revenue participation fee of 15% of all gross monthly sales of cannabis, cannabis-infused products and noncannabis products produced at the Massachusetts Cannabis Center. The report noted that the manufacturing of cannabis-infused products, including the 1906 branded Drops, Howl’s Tincture and Harpoon Extracts, has increased dramatically at the center, with projected sales of manufactured infused products expected to be even stronger. “The June 2022 financial results highlight the strength of our operations,” said AmeriCann CEO and president Tim Keogh in the press release. “Record revenue, combined with our high gross margins and low operating costs, resulted in all-time profits and cash flow for the company. Additionally, July 2022 revenue, which was not included in the most recent quarterly financials, set a monthly record.”

To view the full press release, visit https://cnw.fm/LtoHT

About AmeriCann Inc.

AmeriCann develops and leases cannabis cultivation, processing and product manufacturing facilities. The company uses greenhouse technology, which is superior to the current industry standard of growing cannabis in warehouse facilities under artificial lights. According to industry experts, by capturing natural sunlight, greenhouses use 25% fewer lights and utility bills are up to 75% less than in typical warehouse cultivation facilities. As such, AmeriCann’s Cannopy System enables cannabis to be produced with a greatly reduced carbon footprint, making the final product less expensive. Additionally, greenhouse construction costs are nearly half of warehouse construction costs. AmeriCann is also designing GMP-certified cannabis extraction and product manufacturing infrastructure. The company has secured licenses to produce cannabis-infused products, including beverages, edibles, topicals and concentrates. AmeriCann plans to operate a marijuana product manufacturing business at the Massachusetts Cannabis Center. For more information about the company, please visit www.Americann.co.

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Releases Financial Results for H1 2022

Flora Growth (NASDAQ: FLGC), a manufacturer and distributor of global cannabis products and brands, is reporting its financial and corporate results for the six months ending June 30, 2022. Highlights of the report include revenue for the company increasing 604% from the same period last year, reaching ~$15 million while gross profit for the company increased to ~$7 million, an increase of 547%. In the report, the company reaffirmed its 2022 revenue guidance of $35 million to $45 million, which represents an increase in projected revenue of between 300% to 400%. “In the first half of 2022, Flora delivered on its promise to double revenue compared to the second half of 2021, and we expect to maintain that trajectory to deliver our full year guidance as a result of continued growth in our House of Brands, the launch of several new brands in the United States, and the commencement of sales in our Commercial Wholesale and Life Sciences business,” said Flora Growth CEO and chair Luis Merchan in the press release. “We started 2022 with the integration of both Vessel and JustCBD, and despite macro headwinds in the global markets as well as global cannabis regulations, we are extremely pleased with our growth year-to-date. We are also seeing positive movement in our Life Sciences division with progress on the approval of our clinical trials in the United Kingdom and the acquisition of Masaya, a science-backed, high-potency CBD brand. . . . We continue to prudently manage our overhead and working capital as we expect to improve profitability going forward. With all three of our core pillars generating revenue in the second half of 2022, continued gross margin expansion and a focus on streamlining operating expenses, we believe we have a path to profitability that few global cannabis companies can achieve in this difficult environment.”

To view the full press release, visit https://cnw.fm/Y6kh5

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the extensive outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to commercial, house of brands and life sciences divisions. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Four Partnerships, Boosts ‘Revenue Picture’

Lexaria Bioscience, a global innovator in drug delivery platforms, recently announced partnerships with Premier Wellness Science Co., BevNology, AnodGen Bioceuticals, and Valcon Medical A/S
According to coverage by Zacks Small-Cap Research, who value Lexaria at $15 per share, the most impactful of these partnerships is with Premier because the company is expected to start paying license fees in early September
In a June 7 Fireside Chat, Lexaria Chair and CEO Chris Bunka disclosed that the company is capitalizing on partnerships with “national players in different areas of the world” to improve its “revenue picture” and offset its cash burn
In the longer term, the company is targeting milestone payments from large national and international consumer companies and pharmaceutical organizations

In a June 7 Fireside Chat hosted by John D. Vandermosten, CFA, of Zacks Small-Cap Research (“SCR”), Lexaria Bioscience (NASDAQ: LEXX) Chair and CEO Chris Bunka expressed hope that the then-ongoing negotiations with “national players in different areas of the world” would yield contracts that would significantly improve its revenue (https://ibn.fm/qhlo1). The negotiations led to separate announcements that form the basis of Zacks SCR’s latest coverage of the company, who value Lexaria at $15 per share (https://ibn.fm/OvOaJ).

“Lexaria experienced a substantial amount of activity on both the drug development front and in closing agreements with partners since the end of the fiscal second quarter,” Zacks notes in its coverage (https://ibn.fm/sGXzP). “The company announced four material partnerships in June that will provide a variety of upfront, milestone, and royalty opportunities over the next quarters and years to come.”

Lexaria announced partnerships with Premier Wellness Science Co., BevNology, AnodGen Bioceuticals, and Valcon Medical A/S. The most impactful of these, the Zacks report notes, is with Premier because the company is expected to start paying license fees and launch its products using Lexaria’s patented DehydraTECH(TM) technology in Japan. The agreements with AnodGen and Valcon, on the other hand, are longer-term in nature.

As detailed in a June 3 press release, Lexaria granted an exclusive license to Premier authorizing the latter’s use of its DehydraTECH technology in various cannabidiol (“CBD”) products that may be in oral liquid or non-liquid form. In addition, per the terms of the agreement, DehydraTECH may also be used in topical, hair-care, lip-care, and cosmetics segments (https://ibn.fm/3cnkt).

“The arrangement includes minimum payments of $4.5 million to be paid over the first five years of the deal to maintain exclusivity,” Zacks SCR explains. “The license payments will start from a small base and grow as the arrangement moves into its final years. First payments will be made to Lexaria on September 1. Royalty percentages were not disclosed, nor were Premier sales forecasts; however, the press release noted that under the worst-case sales projection by Premier, Lexaria could receive annual royalties of over $5 million.”

The license and royalty payments are part of a short-to-medium-term revenue-generation strategy, with the company eventually targeting milestone payments from companies primarily in the pharmaceutical sector as part of its longer-term strategy. And to make its DehydraTECH technology more attractive for large national and international consumer companies and pharmaceutical organizations, Lexaria has invested a lot of time and resources in validating its R&D programs (https://ibn.fm/ZulHA).

“If people are unaware, for small pharma companies like ourselves, our most likely path to commercial success comes through milestone payments with pharma where you elevate, through Phase I, into Phase II, and so on, a drug or delivery system. And usually, those payments are quite large, usually, tens of millions and sometimes hundreds of millions of dollars, [and can cover our R&D programs]. And I want to assure our shareholders that we want to be able to cover these programs without issuing any more equity,” Chris Bunka said during the Fireside Chat.

In the interim, Lexaria has maintained tremendous fiscal prudency while supporting its R&D programs. According to Bunka, the company’s spending is within its projected budgetary expectations, having raised $15 million in 2021. Currently, the company has between $7-8 million in its bank accounts, which it projects will support its operations through the third quarter of 2023. But by partnering with the companies such as Premier, Lexaria is making strides to improve its “revenue picture” and offset “more of our cash burn.”

Lexaria is a global innovator in drug delivery platforms that has developed DehydraTECH, shown to improve the bioavailability, speed of onset, and brain absorption of pharmaceuticals and therapeutics.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW – Report Says Senate Intelligence Committee Chair Toned Down Cannabis Amendment to Ease Bill Passage

Cannabis reform is still quite controversial. Reform activists have had a hard time getting reform past lawmakers who oppose cannabis for a variety of reasons. In many cases, they have been forced to give up certain provisions in their cannabis initiatives to make them more palatable to Republican and Democratic lawmakers who were withholding their support. A recent report from the Senate Intelligence Committee has revealed that the panel did just that last month.

In late June, the Senate committee voted in favor of a measure that would make it possible for people who had used cannabis in the past to work for intelligence agencies such as the Central Intelligence Agency (CIA) and the National Security Agency (NSA). The measure was then attached to the Intelligence Authorization Act, which was slated to go through both chambers before reaching the president’s desk. However, the report says that the committee adopted a scaled-back version of the original proposal instead.

The original version, which would have provided cannabis users with even more protections, was dialed down to make it more attractive and increase its chances of passing. In fact, the vote tally reveals that the scaled-back version of the proposal even drew the support of notorious antilegalization lawmaker Senator Tom Cotton. The proposal was first introduced by Senator Ron Wyden and attached to the Intelligence Authorization Act as an amendment.

The report notes that the proposal would have barred any federal agency from limiting their employees’ access to classified information due to past or current marijuana use. However, a scaled-back, second-degree amendment from Chairman Mark Warner and Senator Michael Bennet toned down Wyden’s original proposal and limited cannabis protections to individuals working for federal intelligence agencies.

Furthermore, the scaled-down amendment changed the language from “past or present” marijuana use to “pre-employment” marijuana consumption. According to a spokesperson from Warner’s office, Warner offered the revised proposal after the first version of the amendment failed to garner enough votes. Ultimately, the revised amendment passed in an 11 to 5 vote that saw notable members of the senate such as Senators Cotton, Diane Feinstein and Susan Collins — all of whom have a long history of opposing cannabis reform — supporting the legislation.

However, this vote may be indicative of a shift in perspective for the two latter senators, especially in regard to modest cannabis reform. Collins has previously supported proposals on access to cannabis by veterans and cannabis banking reform while Feinstein is a proponent of cannabis research.

While the cannabis industry and its actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) would have preferred to see sweeping marijuana reforms at the federal level, the incremental approach now seems the more realistic way, and advocates need to exercise patience as the process plays out over time.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — NIH Seeks Input on Cannabis Research Barriers

In a request for information published last week, the National Institutes on Health (NIH) indicated that marijuana has been used for thousands of years for therapeutic purposes despite the lack of sufficient data supporting such medicinal use. The agency is now looking to identify the barriers that have been making it hard for the scientific community to study this plant and its constituents.

In that notice, the top federal agency revealed that eight agencies under its umbrella are partnering in this effort to collect information spelling out why conducting cannabis research is difficult. The barriers could include the current federal classification of the substance as a Schedule 1 drug.

The NIH goes on to say that despite the fact that the U.S. Food & Drug Administration has approved therapies that are based on cannabinoids, there is no scientific basis to support some of the medical uses for which cannabis has been legalized at state level. For that reason, the agency wants to know the barriers in the way of conducting research to ascertain the specific benefits or potential risks associated with using marijuana to manage different health conditions. Such needed research would provide scientific proof of the efficacy or otherwise of marijuana for different clinical indications so that policymakers and the general population can make informed decisions.

The notice spells out some of the barriers hindering marijuana research. These include unanticipated costs incurred during the process of obtaining a license to conduct a study on marijuana, lack of an appropriate quantity and quality of research-grade marijuana as well as a shortage of the right tools to measure different aspects of marijuana use.

The note mentioning the lack of suitable marijuana products for research may be an indirect reference to the fact that for several decades, only one government-owned facility in Mississippi was allowed to produce the marijuana used for research purposes. Numerous complaints have been voiced about the quality of this marijuana, with some saying it was closer to hemp than the marijuana people access in state-legal retail outlets. The Drug Enforcement Administration has since granted licenses to additional suppliers and manufacturers, and there is pressure to permit scientists to gain direct access to the marijuana products sold in retail outlets so that any research done reflects the realities of what people are using.

The RFI published says that the agency wants to gain a better understanding of those barriers and eventually come up with remedies to ease the work of studying marijuana. The NIH also outlined the specific aspects it was interested in obtaining input about. Those include the research gaps where data is needed, the desirable infrastructure to facilitate the needed research, how the NIH can help expand scientific research into cannabis and so on. The deadline for receiving the input is Oct. 15, 2022.

Hopefully, the information gathered will result in the implementation of much-needed reforms so that industry actors such as Prime Harvest Inc. can avoid jumping through endless hoops whenever they want to conduct studies geared at furthering their corporate goals.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – LFTD Partners Inc. (LIFD) Releases Q2 2022 Financial Report

LFTD Partners (OTCQB: LIFD), the corporate parent of leading cannabis and psychedelics manufacturer Lifted Made, is reporting on its second quarter 2022, which is the period ended June 30, 2022. Highlights of the report include revenue for the quarter totaling $16,776,502, a 151% increase from the $6,695,144 reported in Q2 2021, and an increase in operating margin of 3.14%, with Q2 2022 coming in at 26.40%. GAAP net income from the quarter increased — the eighth consecutive quarter of upward movement — totaling $3,219,460 up from $1,596,154 the same period last year. The company reported a 64% increase in basic earnings per share (“EPS”), which went up from $.14 in second quarter 2021 to $0.23 per share Q2 2022; diluted EPS was also up, showing an 82% increase from $0.11 to $0.20 per share. The company noted that basic and diluted weighted average shares outstanding for the three months were 14,099,007 and 15,906,205, respectively. LFTD reported more than $3.751 million cash on hand at the end of the quarter, with an increased inventory of $10,049,245, up from $3,809,944. The company’s current assets totaled $19,678,947, a 50% increase over the same period last year, with working capital going up 725%, totaling $10,284,320, up from $1,246,426. “Q2 2022 was a record quarter for us in terms of net income, earnings per share and free cash flow,” said LFTD Partners COO and vice chair and Lifted Made founder and CEO Nicholas S. Warrender in the press release.

To view the full press release, visit https://cnw.fm/Tq18F

About LFTD Partners Inc.

LFTD Partners is focused on acquiring rapidly growing and profitable companies that sell branded hemp-derived cannabinoid products, emerging psychedelic products and other alternative lifestyle products. LFTD Partners’ first wholly owned subsidiary is Lifted Made, which sells award-winning, hemp-derived cannabinoid products and other psychedelic and alternative lifestyle products under its flagship brands Urb Finest Flowers and Silly Shruum. LFTD Partners also owns percentages of CBD-infused beverage and products maker Ablis and distillers Bendistillery Inc. (d/b/a Crater Lake Spirits) and Bend Spirits Inc., all located in Bend, Oregon. For more information about the company, please visit www.LFTDPartners.com and www.LiftedMade.com.

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.